JLHL Q4 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹387.8 Cr
verified against source
Revenue YoY
15.1%
reported change
EBITDA
₹89.2 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Jupiter Life Line Hospitals delivered solid Q4 FY26 with revenue of Rs 387.8 crore (+15.1% YoY) and PAT of Rs 50.2 crore (+11.5% YoY), though EBITDA margin contracted approximately 100bps from year-ago to 23%. The newly commissioned Dombivli hospital (opened February 2026) is in early ramp-up phase with insurance empanelment expected in 6-12 months; management targets EBITDA break-even by Q4 FY28. The base hospital business (Thane, Pune, Indore) shows healthy occupancy trends with Thane at 75% and Pune at 65%. Expansion pipeline remains on track: Pune South (CY28), Mira Road (excavation by year-end), and BKC (400 beds, regulatory clearances ongoing). Balance sheet remains robust with gross debt of Rs 500 crore against cash of Rs 545 crore. Key risk: 2-3 crore monthly EBITDA burn at Dombivli will weigh on near-term consolidated margins until occupancy improves.
Colored figures show movement against the previous available record.
Guidance to track
- Two years from February 2026 commissioning, the Dombivli hospital should achieve EBITDA breakeven, with insurance empanelment expected in 6-12 months post-accredititation.
- At current capacity, Thane should grow at inflation-linked rates while Pune will benefit from occupancy expansion and case mix improvement. Indore has all three growth levers active.
- Pune South expansion on track for CY28 opening as committed. Mira Road has completed architectural drawings and expects excavation to begin by year-end.
- Internal cash generation over next 4-5 years combined with debt up to 3x EBITDA should fund all announced projects including BKC without requiring external capital.
Risks flagged
- Management flagged that the depreciating rupee and cost of capital expenditure threatens to balloon project costs. This is particularly relevant for the Rs 1.5 crore per bed average capex across 1,700 new beds.
- While initial doctor and community response is encouraging, Dombivli faces 2-3 crore monthly EBITDA drag for ~2 years. Insurance empanelment lags by 6-12 months post-accredititation, creating a revenue gap.
- Analyst asked about Thane hospital expansion approvals - management acknowledged interim approvals received but not final. They cannot finalize expansion scope or timeline until regulatory clearance is complete.
- Analyst asked whether Jupiter would pursue international medical tourism given government initiatives. Management explicitly rejected this strategy, stating they prefer focusing on domestic demand which is sufficient for their capacity plans.
Key quotes
- We are not trying to just grow fast. We are trying to grow right. Every project in our pipeline is greenfield. Each one is designed as a fullscale hub. Not a spoke, not a satellite, but a flagship facility in its own right.
- Our internal accruals that we'll generate over the next five years along with some debt as I said with a currently self-imposed ceiling of three times EBITDA, we believe that a combination of these two should take us through the line of everything including BKC.
- The only thing that I'm watching out for very keenly is the depreciating rupee and the cost of capex. So that is kind of a national reality. If the situation does not come under good control, it threatens to really balloon.
Research modules